ACC supports both clinical and commercial viral vector production
Andelyn Biosciences, Inc., a gene therapy contract development and manufacturing organization (CDMO), has added a new good manufacturing practice (GMP) clinical and commercial manufacturing facility, the Andelyn Corporate Center (ACC), to its network of sites that support cell and gene therapy (CGT) development and manufacturing.
Located in Columbus, OH, the ACC is an advanced 200,000 square-foot gene therapy GMP clinical and commercial manufacturing facility. The site has capability to support any scale of gene therapy viral vector production using various modalities including adherent, iCELLis, and suspension platform capacity of up to 8 X 2000L.
“We built the ACC in response to increasing customer demand for regulatory-compliant, high quality, scalable viral vector production. … It demonstrates Andelyn’s commitment to providing end-to-end services for the accelerated delivery of critical gene therapies to patients,” says Eric Blair, the CDMO’s chief commercial officer. “Our clients are choosing us as their strategic partner for our flexibility, experience, and patient focus.”
In addition to the ACC launch, Andelyn has recently added to its service offerings. Clients will have access to Andelyn’s own high-quality cell line and plasmids that are licensed with accessible terms to clients, with some available immediately off the shelf.